Bruker Corporation (NASDAQ:BRKR) announced that it is expanding its strategic collaboration with Atinary Technologies Inc., and acquiring a minority stake in the Lausanne-based company. The financial terms of the deal were not disclosed, according to the press release.

This collaboration aims to integrate Chemspeed’s laboratory automation platforms, Bruker’s analytical instruments and SciY’s scientific software into Atinary’s SDLabs platform. The SDLabs platform uses artificial intelligence agents and machine learning to design experiments and automate closed-loop workflows for research and development.

Atinary and Chemspeed have set up a joint demonstration laboratory at Chemspeed’s headquarters, located near Basel, Switzerland. Atinary’s autonomous laboratory in Boston opened its doors in early 2026 and incorporates Chemspeed robotic equipment as well as Bruker benchtop NMR instruments, with a focus on small-molecule synthesis and catalysis in the field of pharmaceutical R&D.

“Atinary’s mission is to augment human capabilities through AI and robotics, in order to exponentially accelerate scientific discovery and tackle major global challenges,” said Dr Hermann Tribukait, co-founder and CEO of Atinary Technologies.

Bernd Gleixner, president of Bruker’s Chemspeed division, said that this investment advances Bruker’s goal of combining analytical technologies with laboratory automation, scientific software and AI-guided experimentation.

Source: Press Release | The Atinary team last spring in Boston, while opening a Self-Driving Labs® facility. © Atinary

The post Bruker expands its collaboration with Atinary and makes a minority investment appeared first on BioAlps.

The Swiss Gender Medicine Symposium is taking place on 26 and 27 October 2026 at the Kursaal Bern

Gender medicine has long since answered the question of whether biological sex and gender play a role. The evidence is there. What remains is the more difficult task: translating this knowledge into clinical practice, research structures, and health policy. That is precisely what this symposium is all about.

On October 26 and 27, 2026, the second Swiss Gender Medicine Symposium at the Kursaal Bern will bring together leading voices from clinical practice, research, and health policy, from Switzerland and around the world. The program is aimed at professionals in medicine, research, public health, industry, and politics and covers clinical guidelines, global health, men’s health, medical education, as well as AI and bias in big data.

26 – 27 October 2026 | Kursaal Bern | Information and Registration

The post Swiss Gender Medicine Symposium appeared first on BioAlps.

Alcon, the Geneva-based global leader in eye care, announced on Monday evening that it is discontinuing its intraocular lens (IOL) programmes, technology it acquired through the 2019 purchase of PowerVision for $285 million. These lenses were primarily designed for use in cataract surgery, replacing the eye’s clouded natural lens.

Alcon has its global headquarters in Geneva and operates a manufacturing and research site in the canton of Fribourg, underscoring the company’s deep roots in Switzerland.

The PowerVision programmes “did not produce acceptable clinical outcomes in patients, particularly due to unpredictable and persistent post-operative visual outcomes in a subgroup of patients – issues that could not be resolved despite multiple development efforts”, Alcon emphasised on Monday evening.

The decision triggered a $402 million impairment charge, wiping out the Swiss Health Valley company’s earnings per share for the second quarter. The news is harsh, but not a catastrophe: Alcon’s share price has continued to rise, suggesting investors see the setback as a one-off rather than a sign of broader trouble.

That resilience is reinforced by Alcon’s broader innovation pipeline. Early July 2026, the company announced a non-exclusive collaboration with American company RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), combining RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to let surgeons fine-tune visual outcomes after cataract surgery.

Under the deal, RxSight receives a $60 million upfront payment, with up to $140 million more tied to development and regulatory milestones; Alcon will lead global commercialization while RxSight handles development and manufacturing. The partnership suggests Alcon is moving quickly to rebuild momentum in the IOL space even as it winds down the PowerVision-derived programmes.

Sources: swissinfo.ch, Alcon Investor Relations | ©Alcon

The post Alcon Halts Intraocular Lens Programmes After $402 Million Writedown appeared first on BioAlps.

The SICTIC Investor Day at Fongit is taking place on 24 September 2026 in Plan-les-Ouates.

On 24 September 2026, join SICTIC at FONGIT in Geneva for an Investor Day, where groundbreaking startups meet forward-thinking investors. This event, hosted at Geneva’s premier innovation incubator, is ideal for those looking to discover new ideas and network with leaders in the startup ecosystem.

What to expect

• Startup Pitches: Get a first look at promising startups across various industries as they present their innovative ideas to investors ready to fuel their growth.
• Networking at FONGIT: Connect with investors, entrepreneurs, and key players in Geneva’s vibrant tech and innovation community.
• Incubator Insights: Experience FONGIT, a leading hub for startup incubation, and engage with the minds behind its success.

24 September 2026 from 6.30 PM | FONGIT HQ in Plan-les-Ouates | More Information

The post SICTIC Investors Day at FONGIT appeared first on BioAlps.

Apply before 25 September 2026 for the Eureka Biotech programme, in collaboration with Innosuisse

Project applications with a clear innovation content and implementation plan in biotech areas like medicine, bioinformatics, pharmaceutical products and services, life sciences, digitalization, (bio)process technology (non-exhaustive list of cooperation areas) are welcome. Check call outline for topics and scope.

The countries taking part in this call for projects include Austria, Belgium (Wallonia and Flanders), Canada, Chile, Estonia, France, Germany, Lithuania, The Netherlands, Portugal, South Africa, South Korea, Spain, Sweden, Switzlerand and Türkiye. Your R&D project must include at least two organisations based in at least two of the countries participating in this cooperative call for projects.

Submissions to both the Eureka Smart Simple platform and the Innosuisse platform are required by 25 September 2026.

Application Deadline : 25 September 2026 | More information

The post Eureka Biotech appeared first on BioAlps.

Oculis Holding AG, a Zug-based biopharmaceutical company with operations in Lausanne, has had a decisive first two weeks of August 2026, combining positive US regulatory feedback with a strategic acquisition that together strengthen its position in neuro-ophthalmology.

Positive FDA pre-IND feedback for acute MS relapses

On August 3, Oculis announced that the FDA’s Division of Neurology had given positive pre-IND feedback on a regulatory pathway for Privosegtor, the company’s novel neuroprotective peptoid candidate, in acute multiple sclerosis (MS) relapses. The FDA confirmed that Oculis can cross-reference existing Privosegtor data from its open IND, meaning no additional preclinical studies are required before filing. An IND submission for this new indication is planned for the fourth quarter of 2026.

The move builds on Privosegtor’s Phase 2 ACUITY results in optic neuritis — a common type of MS relapse — where the candidate improved visual function, preserved retinal ganglion cell integrity, and reduced neurofilament levels, a marker of axonal injury. “Building on positive Phase 2 ACUITY data in optic neuritis, we believe Privosegtor has the potential to mitigate neuroaxonal damage and improve recovery following acute relapse events,” said Riad Sherif, M.D., CEO of Oculis. MS affects an estimated 2.8 million people worldwide, with around 170,000 relapses occurring each year in the US alone, and no neuroprotective therapy is currently approved for this indication.

Full acquisition of Privosegtor from Accure Therapeutics

One week later, on August 10, Oculis announced an asset purchase agreement with Barcelona-based Accure Therapeutics to acquire full worldwide development and commercial rights to Privosegtor, terminating the companies’ existing license agreement along with its associated milestone payments and royalties. The deal also includes ACT-02, an early-stage preclinical neurology candidate from Accure, in a separate closing.

Consideration for both assets totals a $3.8 million upfront cash payment plus up to 2,050,000 Oculis ordinary shares, subject to lockup release over two years or vesting on development and regulatory milestones. Closing for Privosegtor is expected by February 28, 2027, and for ACT-02 by March 31, 2027. “By terminating our legacy license agreement with Accure, we can secure global commercial rights to this unique, long-term asset at significantly reduced royalties as we build a leadership position in neuro-ophthalmology,” said Sherif.

Together, the two announcements give Oculis clearer ownership economics and a widening regulatory runway for Privosegtor, which is already advancing through the pivotal PIONEER-1 trial in optic neuritis. The Swiss Health Valley company plans to host an R&D Day in the fourth quarter of 2026 to share further details on both programmes.

Source: Press Release | ©Oculis

The post Oculis Secures FDA Backing and Full Ownership of Privosegtor appeared first on BioAlps.

Health VC Summit is taking place from 2 to 3 September in Zürich. The events brings together three regions: China, Saudi Arabia and Europe.

Europe, China, and Saudi Arabia are shaping the next chapter of healthcare investment. HealthVC Summit 2026 brings these three innovation ecosystems together in Zurich for two days focused on cross-border investment, partnerships, and scaling health startups.

Day 1: Investor Summit
• Cross-border healthcare investment strategies
• Sovereign wealth and VC perspectives
• Co-investment and market expansion discussions

Day 2: Startup Summit
• Startup Showcase
• One-on-One Funding Clinics
• Strategic Partner Labs
• Sector Deep Dives across BioTech, MedTech, Digital Health, Health Data, and AI

2 to 3 September 2026 | Zürich, Switzerland | Investor and Startup passes available by application | Information and registration

The post Health VC Summit appeared first on BioAlps.

Apply before 7 September 2026 for the Foire du Valais Pitch Contest organised by The Ark. The call for project is for Valais-based projects only.

The Foire du Valais Pitch Contest returns in 2026. Organised by The Ark Incubator, it offers young Valais-based startups the chance to present their project to a wide audience, gain visibility and win over a jury of experts. Ten start-ups will be selected to take to the stage, and two of them will win a prize of CHF 2,000. Applications are now open.

Application Deadline: 7 September 2026 | Apply here

The post Pitch Contest – Foire du Valais appeared first on BioAlps.

Apply before 31 August 2026 for the EPFL Investors Day, and pitch at one of Switzerland’s largest investment event

EPFL Startup is now accepting applications for EPFL Investor Day 2026, which brings together leading investors and groundbreaking deep-tech start-ups.

Entrepreneurs in Western Switzerland who are preparing to raise funds or are currently in the process of doing so can apply to present a project to investors and accelerate their growth.

25 November 2026 | SwissTech Convention Centre, Lausanne | Apply by 31 August 2026

The post EPFL Investors Day – Call for Project appeared first on BioAlps.

MedTech MasterClass — Understand, Decide, Act, organised by Humanae Partner, is taking place on 15 September 2026 at Impact Hub Lausanne.

This half-day face-to-face session for managers and executives wishing to understand, assess and make decisions regarding a proposed entry into the MedTech sector. The GoNoGo method, regulatory compliance, go-to-market strategy.
You will gain a better understanding of the following topics:
• Assessing whether your MedTech project is viable before committing significant resources
• Understanding the regulatory framework for medical devices [MDR (EU) 2017/745]
• Using the GoNoGo method to objectively assess your decision to launch or maintain a product on the market
• Identifying hidden costs, organisational risks and strategic levers
• Mitigating the risks of your market entry strategy

15 September 2026 | Impact Hub, Lausanne | Register (Fee from 185 CHF)

The post MedTech MasterClass — Understand, Decide, Act appeared first on BioAlps.